NEW YORK, July 14, 2026, 16:13 EDT
Shuttle Pharmaceuticals Holdings, Inc. NASDAQ:SHPH shares closed 40.5% higher at $4.16 on Tuesday after 52.56 million shares changed hands. Share turnover — volume divided by shares outstanding — reached about 82.5 times the company’s 637,000-share base, while activity ran 22.6 times its average. The tape was the story.
| July 14 measure | Reading | Comparator | Result |
|---|---|---|---|
| Closing price | $4.16 | $2.96 previous close | +40.5% |
| Session high | $5.10 | $2.96 previous close | +72.3% |
| Trading volume | 52.56 million | 2.33 million average | 22.6 times |
| Trading volume | 52.56 million | 637,000 shares outstanding | 82.5 times |
| Close versus high | $4.16 | $5.10 | -18.4% |
The move came a day after HRT Financial LP, reported as a 10% owner, filed a Form 4 showing purchases of 8,997 shares for about $30,212 on July 9 and 10. HRT says it is a quantitative trading firm that provides liquidity in global markets, and the filing did not identify it as a Shuttle officer. That distinction matters.
The wider transaction record was less one-sided. Across July 6-10, HRT’s sales exceeded its later purchases by 29,136 shares and about $101,915 in cash at the disclosed prices, before fees. Its holding ended at 61,271 shares, 32.2% below the 90,407 held after a July 2 purchase. The latest buy was a partial rebuild.
| HRT transaction | Shares | Price | Holding after |
|---|---|---|---|
| July 2 purchase | 7,851 | $3.54 | 90,407 |
| July 6 sale | 9,022 | $3.51 | 81,385 |
| July 7 sale | 10,580 | $3.33 | 70,805 |
| July 8 sale | 18,531 | $3.52 | 52,274 |
| July 9 purchase | 8,266 | $3.38 | 60,540 |
| July 10 purchase | 731 | $3.11 | 61,271 |
| Net, July 6-10 | 29,136 sold | About $101,915 cash inflow | 61,271 |
Tuesday’s high was 72.3% above Monday’s close, but the stock finished 18.4% below that peak. The Nasdaq Biotechnology Index lost 0.46%, pointing to a company-specific trade rather than a sector rally. Momentum was strong, but it did not hold every gain.
No new operating update accompanied the rally; the company’s investor site listed June 26 as its latest release. That statement said United Dogecoin had bought its first mining units, expected deployment in about 60 days and secured hydroelectric power at 6.4 cents per kilowatt-hour. Co-Chief Executive Ryan Trasolini said, “In approximately 60 days, our miners are expected to be online, leveraging renewable power and establishing a foundation for future growth.” Deployment remains subject to delivery and installation schedules. The market wants proof. Shuttle Pharmaceuticals
The latest reported balance sheet, dated March 31 and before the May financing, showed $1.09 million of cash against $8.31 million of current liabilities. Shuttle reported no first-quarter revenue and a $2.15 million net loss. On May 6, its private investment financing closed with the issuance of $9.55 million of Series B-2 preferred stock and warrants. The terms matter as much as the headline amount.
Preferred securities issued for the United Dogecoin merger, an adviser fee and the financing can convert into about 46.2 million common shares on pre-split terms, subject to stockholder approval and ownership caps. After the June 11 reverse split combined every 10 shares into one, that equals roughly 4.62 million shares, or 7.3 times the current common share count, before attached or milestone warrants. The small share base may not stay small.
But the setup can cut both ways. A small post-split share count can amplify price moves, and a confirmed mining launch could give investors a new operating benchmark. Delivery delays, approval of the conversions, warrant exercises or more financing could instead clear a path for much more supply. The risk is two-sided.
For investors, the next hard markers are whether the miners go online on the company’s schedule and how the convertible securities are handled. Until then, Tuesday’s price action says more about a small share base and rapid turnover than about a newly reported change in the business. Timing matters here.
